Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have been assigned an average rating of “Hold” from the ten research firms that are covering the firm, Marketbeat reports. Six analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $40.00.

A number of research firms have recently weighed in on SNN. Zacks Investment Research raised shares of Smith & Nephew SNATS from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research note on Wednesday, June 7th. BidaskClub cut shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Finally, Goldman Sachs Group, Inc. (The) cut shares of Smith & Nephew SNATS from a “buy” rating to a “neutral” rating in a research note on Monday, February 27th.

TRADEMARK VIOLATION NOTICE: This news story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/06/19/smith-nephew-snats-inc-snn-receives-consensus-rating-of-hold-from-analysts.html.

Shares of Smith & Nephew SNATS (NYSE:SNN) traded down 0.14% during mid-day trading on Monday, hitting $35.18. 259,092 shares of the stock traded hands. The firm has a market cap of $15.38 billion, a price-to-earnings ratio of 20.03 and a beta of 0.79. The firm’s 50 day moving average price is $34.52 and its 200 day moving average price is $31.56. Smith & Nephew SNATS has a 12-month low of $26.97 and a 12-month high of $35.82.

A number of large investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. boosted its stake in shares of Smith & Nephew SNATS by 18.8% in the first quarter. Goldman Sachs Group Inc. now owns 237,222 shares of the medical equipment provider’s stock worth $7,337,000 after buying an additional 37,542 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Smith & Nephew SNATS by 51.5% in the first quarter. Point72 Asset Management L.P. now owns 358,700 shares of the medical equipment provider’s stock worth $11,095,000 after buying an additional 121,900 shares during the last quarter. Tyrus Capital S.A.M. acquired a new stake in shares of Smith & Nephew SNATS during the first quarter worth approximately $1,995,000. HighTower Advisors LLC acquired a new stake in shares of Smith & Nephew SNATS during the first quarter worth approximately $242,000. Finally, Paloma Partners Management Co acquired a new stake in shares of Smith & Nephew SNATS during the first quarter worth approximately $200,000. 7.09% of the stock is currently owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Receive News & Ratings for Smith & Nephew SNATS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.